- Patent Title: Neutralizing antibodies to ebola virus glycoprotein and their use
-
Application No.: US16959644Application Date: 2018-12-31
-
Publication No.: US11976109B2Publication Date: 2024-05-07
- Inventor: Nancy Sullivan , Kendra Leigh , John Misasi , Alberto Cagigi
- Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US MD Bethesda
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US MD Bethesda
- Agency: Klarquist Sparkman, LLP
- International Application: PCT/US2018/068198 2018.12.31
- International Announcement: WO2019/136029A 2019.07.11
- Date entered country: 2020-07-01
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61K39/00 ; A61K48/00 ; A61P31/14 ; G01N33/569
Abstract:
Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.
Public/Granted literature
- US20210079067A1 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE Public/Granted day:2021-03-18
Information query
